Acuta Capital Partners’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-45,000
| Closed | -$3.68M | – | 41 |
|
|
2024
Q4 | $3.68M | Sell |
45,000
-90,400
| -67% | -$7.4M | 3.71% | 10 |
|
|
2024
Q3 | $15.5M | Buy |
135,400
+25,000
| +23% | +$2.86M | 12.53% | 1 |
|
|
2024
Q2 | $8.34M | Buy |
110,400
+5,570
| +5% | +$421K | 7.02% | 3 |
|
|
2024
Q1 | $7.16M | Sell |
104,830
-12,543
| -11% | -$857K | 4.65% | 7 |
|
|
2023
Q4 | $7.37M | Sell |
117,373
-3,649
| -3% | -$229K | 4.15% | 6 |
|
|
2023
Q3 | $6.17M | Sell |
121,022
-1,144
| -0.9% | -$58.3K | 4.13% | 11 |
|
|
2023
Q2 | $6.1M | Buy |
122,166
+1,666
| +1% | +$83.2K | 4.13% | 7 |
|
|
2023
Q1 | $4.52M | Sell |
120,500
-24,000
| -17% | -$900K | 3.33% | 13 |
|
|
2022
Q4 | $6.93M | Buy |
144,500
+59,500
| +70% | +$2.85M | 4.26% | 10 |
|
|
2022
Q3 | $2.04M | Buy |
+85,000
| New | +$2.04M | 0.88% | 26 |
|